Ameet Mallik taps fellow Novartis alum to lead business development at ADC Therapeutics
Just one month into his CEO tenure at ADC Therapeutics, Ameet Mallik is bringing in new people to assemble his top team.
David Gilman, a seasoned biopharma consultant who held a brief stint scouting deals for Novartis’ oncology group, is joining the Swiss biotech as chief business and strategy officer.
A veteran of Novartis himself, Mallik jumped to ADC last month after his first CEO experience at Rafael Holdings imploded, replacing Chris Martin, the long-time chief who’d been involved with the company since its formation in 2011 and oversaw a slate of financings, deals, an IPO and an FDA approval.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,400+ biopharma pros reading Endpoints daily — and it's free.